Sol-gel reports third quarter 2024 financial results and provides corporate updates

Mori arkin's appointment as interim ceo as of january 1, 2025 approved by shareholders phase 3 clinical trial of sgt-610 for gorlin syndrome is ongoing with over 40 clinical sites activated sgt-210 proof-of-concept study in patients suffering from darier disease is ongoing ness ziona, israel, nov. 15, 2024 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a phase-3 clinical trial of sgt-610 (patidegib gel, 2%) for gorlin syndrome, and with two approved large-category dermatology products, twyneo® and epsolay®, today announced financial results for the third quarter ended september 30, 2024, and provided a corporate update.
SLGL Ratings Summary
SLGL Quant Ranking